These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27730472)

  • 21. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy.
    Andersen O; Haugaard SB; Hansen BR; Orskov H; Andersen UB; Madsbad S; Iversen J; Flyvbjerg A
    Scand J Infect Dis; 2004; 36(11-12):832-9. PubMed ID: 15764170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement.
    Gómez JM; Gómez N; Fiter J; Soler J
    Horm Metab Res; 2000 Feb; 32(2):66-70. PubMed ID: 10741688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement.
    Roemmler J; Kuenkler M; Schneider HJ; Dieterle C; Schopohl J
    Metabolism; 2010 Mar; 59(3):350-8. PubMed ID: 19800640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients.
    Attanasio AF; Howell S; Bates PC; Frewer P; Chipman J; Blum WF; Shalet SM
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3368-72. PubMed ID: 12107251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency.
    Filipsson Nyström H; Barbosa EJ; Nilsson AG; Norrman LL; Ragnarsson O; Johannsson G
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3185-95. PubMed ID: 22791760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors of cardiovascular disease in GH-deficient adults with hypopituitarism: a preliminary report.
    Bohdanowicz-Pawlak A; Szymczak J; Bladowska J; Bednarek-Tupikowska G; Bidzińska B; Milewicz A
    Med Sci Monit; 2006 Feb; 12(2):CR75-80. PubMed ID: 16449951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
    Biller BM; Sesmilo G; Baum HB; Hayden D; Schoenfeld D; Klibanski A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults.
    Maghnie M; Strigazzi C; Tinelli C; Autelli M; Cisternino M; Loche S; Severi F
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1324-8. PubMed ID: 10199773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.
    Deepak D; Daousi C; Javadpour M; Clark D; Perry Y; Pinkney J; Macfarlane IA
    Growth Horm IGF Res; 2010 Jun; 20(3):220-5. PubMed ID: 20185347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
    Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of growth hormone status on body composition and the skeleton.
    Mukherjee A; Murray RD; Shalet SM
    Horm Res; 2004; 62 Suppl 3():35-41. PubMed ID: 15539797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.
    Weaver JU; Monson JP; Noonan K; John WG; Edwards A; Evans KA; Cunningham J
    J Clin Endocrinol Metab; 1995 Jan; 80(1):153-9. PubMed ID: 7829604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diagnosis of partial growth hormone deficiency in adults with a putative insult to the hypothalamo-pituitary axis.
    Murray RD; Bidlingmaier M; Strasburger CJ; Shalet SM
    J Clin Endocrinol Metab; 2007 May; 92(5):1705-9. PubMed ID: 17327383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adult GH deficiency in Japanese patients: effects of GH treatment in a randomised, placebo-controlled trial.
    Chihara K; Koledova E; Shimatsu A; Kato Y; Kohno H; Tanaka T; Teramoto A; Bates PC; Attanasio AF
    Eur J Endocrinol; 2004 Sep; 151(3):343-50. PubMed ID: 15362963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.